Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VX1.DE Stock Summary
Top 10 Correlated ETFs
VX1.DE
In the News
VX1.DE Financial details
Company Rating
Strong Buy
Market Cap
98.71B
Income
3.62B
Revenue
9.87B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5.4K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
31.39
Forward P/E
22.77
PEG
-16.05
P/S
11.27
P/B
6.6
P/C
-
P/FCF
25.87
Quick Ratio
3.74
Current Ratio
4.08
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
10.28
EPS next Y
16.91
EPS next Q
-
EPS this Y
9.94%
EPS next Y
64.49%
EPS next 5Y
116.01%
EPS last 5Y
25.13%
Revenue last 5Y
18.84%
Revenue Q/Q
1.38%
EPS Q/Q
-
-
-
-
-
SMA20
-2.9%
SMA50
-2.92%
SMA100
10.28%
Inst Own
-
Inst Trans
-
ROA
16%
ROE
23%
ROC
0.21%
Gross Margin
88%
Oper. Margin
40%
Profit Margin
36%
Payout
-
Shs Outstand
258.31M
Shs Float
257.54M
-
-
-
-
Target Price
-
52W Range
285.05-420.0
52W High
-8.32%
52W Low
+35.11%
RSI
50.95
Rel Volume
0.38
Avg Volume
154
Volume
58
Perf Week
1.78%
Perf Month
-0.79%
Perf Quarter
13.03%
Perf Half Y
16.26%
-
-
-
-
Beta
0.351
-
-
Volatility
2.79%, 7.91%
Prev Close
-0.43%
Price
385.05
Change
0.29%
VX1.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 16.22 | 23.89 | 29.39 | 34.87 | 38.3 | |
Net income per share | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | |
Operating cash flow per share | 6.11 | 12.52 | 10.26 | 16.13 | 13.73 | |
Free cash flow per share | 5.82 | 11.52 | 9.35 | 15.33 | 12.72 | |
Cash per share | 14.84 | 25.63 | 29.2 | 42.09 | 43.53 | |
Book value per share | 23.71 | 33.44 | 39.19 | 54.33 | 68.22 | |
Tangible book value per share | 16.69 | 26.5 | 32.2 | 47.72 | 60.74 | |
Share holders equity per share | 23.71 | 33.44 | 39.19 | 54.33 | 68.22 | |
Interest debt per share | 2.6 | 2.63 | 2.58 | 2.4 | 3.31 | |
Market cap | 56.56B | 60.58B | 57.78B | 73.85B | 105.76B | |
Enterprise value | 54.02B | 55.17B | 51.54B | 63.91B | 96.2B | |
P/E ratio | 48.06 | 22.34 | 24.67 | 22.23 | 29.22 | |
Price to sales ratio | 13.59 | 9.76 | 7.63 | 8.27 | 10.72 | |
POCF ratio | 36.04 | 18.62 | 21.86 | 17.88 | 29.9 | |
PFCF ratio | 37.86 | 20.23 | 23.99 | 18.81 | 32.26 | |
P/B Ratio | 9.29 | 6.97 | 5.72 | 5.31 | 6.02 | |
PTB ratio | 9.29 | 6.97 | 5.72 | 5.31 | 6.02 | |
EV to sales | 12.98 | 8.89 | 6.81 | 7.16 | 9.75 | |
Enterprise value over EBITDA | 37.06 | 17.31 | 18.48 | 14.71 | 18.93 | |
EV to operating cash flow | 34.42 | 16.96 | 19.5 | 15.47 | 27.2 | |
EV to free cash flow | 36.16 | 18.43 | 21.4 | 16.28 | 29.34 | |
Earnings yield | 0.02 | 0.04 | 0.04 | 0.04 | 0.03 | |
Free cash flow yield | 0.03 | 0.05 | 0.04 | 0.05 | 0.03 | |
Debt to equity | 0.1 | 0.07 | 0.06 | 0.04 | 0.05 | |
Debt to assets | 0.07 | 0.05 | 0.04 | 0.03 | 0.04 | |
Net debt to EBITDA | -1.74 | -1.7 | -2.24 | -2.29 | -1.88 | |
Current ratio | 3.83 | 5.02 | 4.81 | 5.22 | 3.99 | |
Interest coverage | 20.47 | 49.12 | 45.24 | 78.6 | 86.89 | |
Income quality | 1.33 | 1.2 | 1.13 | 1.24 | 0.98 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.01 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.42 | 0.29 | 0.4 | 0.28 | 0.32 | |
Intangibles to total assets | 0.17 | 0.12 | 0.1 | 0.09 | 0.08 | |
Capex to operating cash flow | -0.05 | -0.08 | -0.09 | -0.05 | -0.07 | |
Capex to revenue | -0.02 | -0.04 | -0.03 | -0.02 | -0.03 | |
Capex to depreciation | -0.71 | -2.37 | -1.87 | -1.38 | -1.43 | |
Stock based compensation to revenue | 0.09 | 0.07 | 0.06 | 0.06 | 0.06 | |
Graham number | 49.45 | 88.61 | 89.52 | 125.92 | 146.83 | |
ROIC | 0.14 | 0.25 | 0.21 | 0.23 | 0.16 | |
Return on tangible assets | 0.17 | 0.26 | 0.19 | 0.2 | 0.17 | |
Graham Net | 8.31 | 16.93 | 20.26 | 30.66 | 29.53 | |
Working capital | 3.4B | 6.26B | 7.14B | 10.25B | 10.6B | |
Tangible asset value | 4.68B | 7.28B | 8.7B | 12.22B | 15.65B | |
Net current asset value | 2.38B | 4.76B | 5.68B | 8.44B | 8.99B | |
Invested capital | 0.1 | 0.07 | 0.06 | 0.04 | 0.05 | |
Average receivables | 521.6M | 759.44M | 1.01B | 1.29B | 1.5B | |
Average payables | 99.3M | 121.37M | 175.07M | 249.45M | 334.4M | |
Average inventory | 145.93M | 224.14M | 316.94M | 406.85M | 599.7M | |
Days sales outstanding | 55.55 | 52.07 | 54.78 | 58.94 | 57.82 | |
Days payables outstanding | 58.38 | 76.91 | 78.72 | 102.68 | 105.52 | |
Days of inventory on hand | 111.62 | 139.19 | 142.54 | 155.62 | 213.64 | |
Receivables turnover | 6.57 | 7.01 | 6.66 | 6.19 | 6.31 | |
Payables turnover | 6.25 | 4.75 | 4.64 | 3.55 | 3.46 | |
Inventory turnover | 3.27 | 2.62 | 2.56 | 2.35 | 1.71 | |
ROE | 0.19 | 0.31 | 0.23 | 0.24 | 0.21 | |
Capex per share | -0.29 | -1 | -0.91 | -0.8 | -1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 8.96 | 9.23 | 9.67 | 9.63 | 0 | |
Net income per share | 3.19 | 2.72 | 3.55 | 4.01 | 0 | |
Operating cash flow per share | 4.2 | 3.5 | 4.4 | 4.92 | 0 | |
Free cash flow per share | 4.07 | 3.33 | 4.17 | 4.76 | 0 | |
Cash per share | 41.96 | 1.3 | 43.6 | 46.23 | 0 | |
Book value per share | 54.16 | 56.07 | 60.03 | 64 | 0 | |
Tangible book value per share | 47.57 | 49.5 | 53.47 | 57.45 | 0 | |
Share holders equity per share | 54.16 | 56.07 | 60.03 | 64 | 0 | |
Interest debt per share | 2.23 | 3.11 | 3.02 | 2.93 | 0 | |
Market cap | 74.08B | 81.58B | 90.62B | 90.02B | 0 | |
Enterprise value | 64.14B | 83.16B | 92.15B | 91.51B | -9.56B | |
P/E ratio | 22.62 | 29.14 | 24.74 | 21.74 | 0 | |
Price to sales ratio | 32.17 | 34.35 | 36.35 | 36.25 | 0 | |
POCF ratio | 68.7 | 90.66 | 79.88 | 70.97 | 0 | |
PFCF ratio | 70.91 | 95.11 | 84.31 | 73.31 | 0 | |
P/B Ratio | 5.32 | 5.65 | 5.86 | 5.45 | 0 | |
PTB ratio | 5.32 | 5.65 | 5.86 | 5.45 | 0 | |
EV to sales | 27.85 | 35.02 | 36.96 | 36.85 | -3.8 | |
Enterprise value over EBITDA | 57.64 | 66.63 | 71.85 | 73.62 | -8.07 | |
EV to operating cash flow | 59.48 | 92.41 | 81.23 | 72.14 | -40.75 | |
EV to free cash flow | 61.39 | 96.95 | 85.74 | 74.53 | -80.68 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Debt to equity | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | |
Debt to assets | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 | |
Net debt to EBITDA | -8.94 | 1.26 | 1.2 | 1.2 | -8.07 | |
Current ratio | 5.22 | 4.28 | 4.14 | 4.08 | 3.99 | |
Interest coverage | 89.09 | 68.33 | 91.64 | 95.24 | 93.25 | |
Income quality | 1.32 | 1.29 | 1.24 | 1.23 | 0.24 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.3 | 0.31 | 0.32 | 0.33 | 0.33 | |
Intangibles to total assets | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | |
Capex to operating cash flow | -0.03 | -0.05 | -0.05 | -0.03 | -0.49 | |
Capex to revenue | -0.01 | -0.02 | -0.02 | -0.02 | -0.05 | |
Capex to depreciation | -0.88 | -1.09 | -1.44 | -0.96 | -1.97 | |
Stock based compensation to revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.08 | |
Graham number | 62.32 | 58.56 | 69.28 | 76.02 | 0 | |
ROIC | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | |
Return on tangible assets | 0.05 | 0.04 | 0.05 | 0.05 | 0.05 | |
Graham Net | 30.57 | -10.79 | 30.37 | 31.83 | 0 | |
Working capital | 10.25B | 9.94B | 10.52B | 11.1B | 10.6B | |
Tangible asset value | 12.22B | 12.74B | 13.78B | 14.82B | 15.65B | |
Net current asset value | 8.44B | 8.42B | 8.99B | 9.48B | 8.99B | |
Invested capital | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | |
Average receivables | 1.41B | 1.5B | 1.55B | 1.55B | 1.55B | |
Average payables | 215.4M | 313.55M | 343.1M | 369.45M | 370.4M | |
Average inventory | 424.4M | 497.85M | 569.3M | 646.1M | 713.75M | |
Days sales outstanding | 56.37 | 58.66 | 56.18 | 55.76 | 55.89 | |
Days payables outstanding | 96.54 | 108.98 | 105.87 | 106.15 | 89.24 | |
Days of inventory on hand | 146.33 | 180.44 | 176 | 194.49 | 180.68 | |
Receivables turnover | 1.6 | 1.53 | 1.6 | 1.61 | 1.61 | |
Payables turnover | 0.93 | 0.83 | 0.85 | 0.85 | 1.01 | |
Inventory turnover | 0.62 | 0.5 | 0.51 | 0.46 | 0.5 | |
ROE | 0.06 | 0.05 | 0.06 | 0.06 | 0.06 | |
Capex per share | -0.13 | -0.16 | -0.23 | -0.16 | 0 |
VX1.DE Frequently Asked Questions
What is Vertex Pharmaceuticals Incorporated stock symbol ?
Vertex Pharmaceuticals Incorporated is a US stock , located in Boston of Ma and trading under the symbol VX1.DE
What is Vertex Pharmaceuticals Incorporated stock quote today ?
Vertex Pharmaceuticals Incorporated stock price is $385.05 today.
Is Vertex Pharmaceuticals Incorporated stock public?
Yes, Vertex Pharmaceuticals Incorporated is a publicly traded company.